Evommune Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-61.32	-66.81	-34.05
Depreciation & Amortization	1.42	1.29	1
Loss (Gain) From Sale of Investments	-1.63	-1.82	-1.75
Stock-Based Compensation	2.15	1.72	1.48
Change in Accounts Payable	-1.83	6.51	0.13
Change in Unearned Revenue	-3	-	3
Change in Other Net Operating Assets	-5.12	0.92	0.22
Operating Cash Flow	-78.25	-58.2	-29.97
Capital Expenditures	-0.13	-0.09	-0.12
Investment in Securities	-25.36	-3.91	-48.32
Investing Cash Flow	-25.49	-3.99	-48.43
Long-Term Debt Repaid	-	-0.42	-0.23
Net Debt Issued (Repaid)	-0.58	-0.42	-0.23
Issuance of Common Stock	0.02	0.01	0.01
Financing Cash Flow	113.62	49.42	63.75
Net Cash Flow	9.88	-12.77	-14.65
Free Cash Flow	-78.39	-58.28	-30.09
Free Cash Flow Margin	-602.96%	-832.61%	-601.76%
Free Cash Flow Per Share	-50.99	-38.64	-24.01
Cash Interest Paid	0.01	0.03	0.06
Levered Free Cash Flow	-	-20.82	-
Unlevered Free Cash Flow	-	-20.8	-
Change in Working Capital	-9.95	7.42	3.34

Updated Oct 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q